Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
News|Articles|May 22, 2025
Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.
Advertisement
Advertisement
As artificial intelligence (AI) seeps more and more into the daily lives of professionals in every industry, cancer care has proven to be no different. In fact, AI-based approaches are already having a dramatic effect on multiple areas of oncology, including treatment selection, the lowering of administrative burden, and drug development.
Related to this article
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
Advertisement
Advertisement